TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03590197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Description: Melatonin 3 mg/ day with Valproate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with Valproate
Study: NCT01082640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Febuxostat placebo-matching capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Febuxostat placebo-matching capsules
Study: NCT00336180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthWise South Africa curriculum
Description: 18 classroom lessons
Study: NCT02259790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/amlodipine fixed-dose combination tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Study: NCT04277507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivaer Stylus
Description: Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
Study: NCT03026153

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group Oral Survey 1
Description: Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention Group Oral Survey 2
Description: Oral Survey 2 will be administered as the intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
Study: NCT02840162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00491738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Oral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sunitinib
Description: Oral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study: NCT00301886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT04092387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying the nicotine content of cigarettes
Description: 1) Altering the nicotine content of the tobacco research cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying the nicotine content of cigarettes
Description: 1) Altering the nicotine content of the tobacco research cigarettes
Study: NCT02204228

Intervention type: DEVICE
Intervention: TITAN™ Reverse Shoulder System (TRS)
Description: All patients will be operated on with the TITAN™ Reverse Shoulder System (TRS).
Study: NCT04591288

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill only protocol
Description: We will implement a 12-wk Treadmill training protocol consisting of treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
Study: NCT01041573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC51 Japanese Encephalitis
Description: 6 mcg or 3 mcg im. at day 0 and day 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC51 Japanese Encephalitis
Description: 6 mcg or 3 mcg im. at day 0 and day 28

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix®720
Description: 0.5 ml im. at day 0 and month 7

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar
Description: 0.5 ml im. at day 0 and day 56 and month 7
Study: NCT03337841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Each subject will receive administration of pembrolizumab 200mg IV once only before curative treatment such as hepatic resection or radiofrequency ablation, and will receive curative treatment after administration of pembrolizumab. After curative treatment, each subject will receive pembrolizumab 200mg IV every 3 weeks. Treatment will continue until tumor recurrence, occurrence of an unacceptable adverse event, or the 16th treatment with pembrolizumab.( The setting of 16 times administration is the period of adjuvant therapy of this trial is 12 month(=48weeks), administration of pembrolizumab is Q3W, so 16 times administration comes to 48 weeks.)
Study: NCT02927223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise treadmill test
Study: NCT02832492

Intervention type: BEHAVIORAL
Intervention: pupil near response

Intervention type: BEHAVIORAL
Intervention: pupil near response
Study: NCT01341873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo APN FCI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychosocial support for caregiver
Description: Undergo APN FCI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: OTHER
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03345212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The rehabilitation program comprises interval ergometer training, dumbbell training, respiratory therapy, mental training and guided walks for 5-7 times/week.
Study: NCT03069768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mSMART
Description: A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chantix
Description: For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chantix
Description: For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
Study: NCT02727114

Intervention type: OTHER
Intervention: Echographic measurement of skin thickness
Description: (Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® \& VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging.

Intervention type: OTHER
Intervention: Echographic measurement of skin thickness
Description: (Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® \& VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging.

Intervention type: OTHER
Intervention: Echographic measurement of skin thickness
Description: (Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® \& VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging.

Intervention type: OTHER
Intervention: Echographic measurement of skin thickness
Description: (Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® \& VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging.
Study: NCT03609229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burch
Description: polyglactin suture was passed through the Cooper's ligament bilaterally with the guidance of the valve

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Sacrocolpopexy
Description: * By careful dissection (to avoid large veins in this region), expose the back of the pubic bone and the lateral aspects of the urethra.~* The right-handed operator double gloves, and places the left hand in the vagina.~* With fingers on either side of the catheter in the vagina, define the urethrovesical junction (at the balloon).~* Place three Ethibond J-shaped sutures on either side of the urethrovesical junction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Sacrocolpopexy
Description: * By careful dissection (to avoid large veins in this region), expose the back of the pubic bone and the lateral aspects of the urethra.~* The right-handed operator double gloves, and places the left hand in the vagina.~* With fingers on either side of the catheter in the vagina, define the urethrovesical junction (at the balloon).~* Place three Ethibond J-shaped sutures on either side of the urethrovesical junction.
Study: NCT04092387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying the nicotine content of cigarettes
Description: 1) Altering the nicotine content of the tobacco research cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varying the nicotine content of cigarettes
Description: 1) Altering the nicotine content of the tobacco research cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarettes
Description: Comparing effects of combining RC2 with EC 1 versus EC2
Study: NCT01721577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXL1717
Description: IGF-1 receptor inhibitor
Study: NCT01536288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhodiola crenulata
Description: Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhodiola crenulata
Description: Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
Study: NCT03574480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (training in use of a Smartphone application)
Description: The intervention group will be added a training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control (Advice on healthy diet and physical activity recommendations)
Description: Advice on healthy diet and physical activity recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control (Advice on healthy diet and physical activity recommendations)
Description: Advice on healthy diet and physical activity recommendations
Study: NCT03577171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: Participants will receive 300mg QD of ABI-H0731 tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC ETV
Description: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC ETV
Description: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Participants will receive matching QD placebo tablets orally.
Study: NCT02666703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb
Description: CytoSorb is a first-in-class extracorporeal cytokine adsorber, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Study: NCT01941992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMITAL®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachets
Study: NCT00519246

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline 5 ml administrated intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Butorphanol tartrate 1 mg i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Butorphanol Tartrate 2 mg i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Flurbiprofen Axetil 50 mg i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Flurbiprofen Axetil 100 mg i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Tramadol Hydrochloride 10 mg i.v.
Study: NCT00887445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV341
Description: 5 - 1000mg once daily
Study: NCT04092387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarettes
Description: Comparing effects of combining RC2 with EC 1 versus EC2
Study: NCT00887445

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01501149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)
Description: DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
Study: NCT04335422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program)
Description: Upper extremity robot-assisted training will include facilitated shoulder flexion-extension, internal-external rotation, abduction-adduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, ulnar-radial deviation, hand finger flexion-extension movements by means of visual feedback with a 3-dimensional virtual environment in which the patient is asked to perform various tasks such as object reaching, grasping, holding, dropping activities by playing computer games.~Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group (routine physical and rehabilitation medicine program)
Description: Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group (routine physical and rehabilitation medicine program)
Description: Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.
Study: NCT04387825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADSVF application in the right hand
Description: 40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
Study: NCT04385927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Net for Parents of Neurodiverse Children
Description: One-on-one distance coached intervention; approx. 12 sessions at 60-90 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Net for Parents of Neurodiverse Children
Description: One-on-one distance coached intervention; approx. 12 sessions at 60-90 minutes.
Study: NCT00745225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: 1 capsule daily, 96 weeks.
Study: NCT03431311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive Cell Therapy (ACT)
Description: T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting mutant transforming growth factor beta receptor type II (TGFβII)
Study: NCT00603967

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dual x-ray absorptiometry (DXA)
Description: Baseline, 6 months, and 12 months

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire
Description: Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months~Cognitive tests - baseline, 6 months, 12 months~Depression assessment - baseline, 6 months, 12 months~Dietary calcium intake questionnaire - baseline
Study: NCT03095248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Continuous twice daily dosing; oral agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Continuous twice daily dosing; oral agent
Study: NCT03334734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169
Description: Once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169
Description: Once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169
Description: Once a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Once a day for 14 days
Study: NCT01456949

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic Arctic Front® Cardiac CryoAblation System
Description: Cardiac cryoablation to isolate the pulmonary veins using the Arctic Front® CryoAblation System, with point ablation using the Freezor® Max as needed.
Study: NCT03046550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTM-1634
Description: NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTM-1634
Description: NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
Study: NCT03365908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Nerve Block
Description: An adductor canal nerve block with 15 mL of 0.5% ropivacaine will be performed pre-operatively by Anesthesiology.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: 15 mL of 0.5% ropivacaine will be administered for the adductor canal block
Study: NCT03874858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib oral 300 mg QD hard capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib oral 300 mg BID hard capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Asciminib orally at a dose of 40 mg BID film-coated tablets (FCT)
Study: NCT04403490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT-ILE
Description: 2 weeks HABIT-ILE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intervention
Description: 2 weeks usual intervention (waitlist group)
Study: NCT01653028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies